bioRxivMicrobiology
In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2
A. M. Szemiel, A. Merits, R. J. Orton, O. MacLean, A. Wickenhagen, G. Lieber, R. M. Pinto, M. L. Turnbull, S. Wang, D. Mair, A. da Silva Filipe, B. J. Willett, S. J. Wilson, A. H. Patel, E. C. Thomson, M. Palmarini, A. Kohl, M. E. Stewart
Abstract
Remdesivir (RDV) is used widely for COVID-19 patients despite varying results in recent clinical trials. Here, we show how serially passaging SARS-CoV-2 in vitro in the presence of RDV selected for drug-resistant viral populations. We determined that the E802D mutation in the RNA-dependent RNA polymerase was sufficient to confer decreased RDV sensitivity without affecting viral fitness. Analysis of more than 200,000 sequences of globally circulating SARS-CoV-2 variants show no evidence of widespread transmission of RDV-resistant mutants. Surprisingly, we also observed changes in the Spike (i.e., H69 E484, N501, H655) corresponding to mutations identified in emerging SARS-CoV-2 variants indicating that they can arise in vitro in the absence of immune selection. This study illustrates SARS-CoV-2 genome plasticity and offers new perspectives on surveillance of viral variants. One Sentence SummarySARS-CoV-2 drug resistance & genome plasticity
- organism: virus
- assay: whole-genome sequencing
- research focus: drug response / drug discovery
- research focus: genome assembly
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Distinct genetic determinants and mechanisms of SARS-CoV-2 resistance to remdesivir
L. J. Stevens, A. J. Pruijssers, … M. R. Denison·bioRxiv·Jan 25, 2022
- Genetic Conservation of SARS-CoV-2 RNA Replication Complex in Globally Circulating Isolates and Recently Emerged Variants from Humans and Minks Suggests Minimal Pre-Existing Resistance to Remdesivir
Ross Martin, Jiani Li, … Evguenia S. Svarovskaia·Antiviral ResearchPeer-reviewed·Feb 6, 2021
- In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.
L. Checkmahomed, V. Du Pont, … G. Boivin·bioRxiv·Feb 7, 2022
- Characterization of various remdesivir-resistant mutations of SARS-CoV-2 by mathematical modeling and molecular dynamics simulation.
S. Torii, K. S. Kim, … T. Fukuhara·bioRxiv·Feb 22, 2022
- Rational Design of the Remdesivir Binding Site in the RNA-dependent RNA Polymerase of SARS-CoV-2: Implications for Potential Resistance
A. Padhi, R. Shukla, T. Tripathi·bioRxiv·Jun 27, 2020
- Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants
J. Pitts, J. Li, … J. P. Bilello·bioRxiv·Feb 9, 2022